Latest Posts
Resources
Epitope Mapping: Alanine Scanning Mutagenesis vs. HDX-MS
Written by: Genya Gorshtein, MSc Published: June 10, 2024 Contents Introduction Alanine Scanning Mutagenesis Epitope Mapping HDX-MS Epitope Mapping [...]
B Cell Sequencing and Polyclonal Sequencing Explained
Written by: Genya Gorshtein, MSc Published: December 12, 2024 Contents Introduction BCR and Single B Cell Sequencing for Antibody [...]
De Novo Sequencing a Bispecific T Cell Engager
Our client is a biotechnology company developing therapeutics that target cancer-specific carbohydrate antigens on the surface of tumour cells.
Antibody Affinity Insights with REpAb Antibody Discovery
Our client is a biotechnology company developing therapeutics that target cancer-specific carbohydrate antigens on the surface of tumour cells.
Functional Enrichment Strategies for Anti-Idiotypic Antibody Discovery
Our client is a biotechnology company developing therapeutics that target cancer-specific carbohydrate antigens on the surface of tumour cells.
SPR vs. ELISA: SPR Guides Accurate ELISA Results
Our client is a biotechnology company developing therapeutics that target cancer-specific carbohydrate antigens on the surface of tumour cells.
Developing CAR-T Therapies Against Novel Cancer Antigens
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
Synthetic Antigens Enable CAR-T Cell Targeting of Solid Tumors
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications